Publications
Selected Publications
1. Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, St Hilare I, Heaton S, Alzamel N, Jackson D, Ralph C, Banerjee S, McNeish I, Bell JC, Melcher AA, Ilkow C, Cook GP, Errington-Mais F. “Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment.” Frontiers in immunology vol. 15 1500570. 23 Dec. 2024.
2. Rezaei R, Boulton S, Ahmadi M, Petryk J, Da Silva M, Kooshki Zamani N, Singaravelu R, St-Laurent G, Daniel L, Sadeghipour A, Pelin A, Poutou J, Munoz Zuniga AI, Choy C, Gilchrist VH, Khalid Z, Austin B, Onsu KA, Marius R, Ameli Z, Mohammadi F, Mancinelli V, Wang E, Nik-Akhtar A, Alwithenani A, Panahi Arasi F, Ferguson SSG, Hobman TC, Alain T, Tai LH, Ilkow CS, Diallo JS, Bell JC, Azad T. “Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.” Nature biomedical engineering, 10.1038/s41551-024-01259-7. 28 Nov. 2024.
3. Wong B, Birtch R, Bergeron A, Ng K, Maznyi G, Spinelli M, Chen A, Landry A, Crupi MJF, Arulanandam R, Ilkow CS, Diallo JS. “High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV?51 activity.” Scientific reports vol. 14,1 28284. 16 Nov. 2024.
4. Taha, Z., Crupi, M. J. F., Alluqmani, N., MacKenzie, D., Vallati, S., Whelan, J. T., Fareez, F., Alwithenani, A., Petryk, J., Chen, A., Spinelli, M. M., Ng, K., Sobh, J., Tanese de Souza, C., Bharadwa, P. R., Lee, T. K. H., Thomas, D. A., Huang, B. Z., Kassas, O., Poutou, J., Gilchrist, V. H., Boulton, S., Thomson, M., Marius, R., Hooshyar, M., McComb, S., Arulanandam, R., Ilkow, C. S., Bell, J. C., & Diallo, J-S. "Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy." Nature Communications, vol. 15, no. 1, 2024, p. 7267. 23 Aug. 2024.
5. Antonova L, Paramanthan P, Falls T, Wedge ME, Mayer J, Sekhon HS, McPherson J, Denroche RE, Gallinger S, Bell JC, Ilkow CS, Chatterjee A. Molecular Characterization and Xenotransplantation of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA). Cancers (Basel). 2024;16(15):2721.
6. Hodgins JJ, Abou-Hamad J, O'Dwyer CE, Hagerman A, Yakubovich E, Tanese de Souza C, Marotel M, Buchler A, Fadel S, Park MM, Fong-McMaster C, Crupi MF, Makinson OJ, Kurdieh R, Rezaei R, Dhillon HS, Ilkow CS, Bell JC, Harper ME, Rotstein BH, Auer RC, Vanderhyden BC, Sabourin LA, Bourgeois-Daigneault MC, Cook DP, Ardolino M. "PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway." Journal of Experimental Medicine. 221(7), 2024.
7. Ilkow CS, Bell JC. Optimizing oncolytic virus design: a "Swiss army knife" approach to create a systemically delivered therapeutic. Signal Transduct Target Ther. 2024 Apr 2;9(1):82.
8. Wong B, Birtch R, Rezaei R, Jamieson T, Crupi MJF, Diallo JS, Ilkow CS. Optimal delivery of RNA interference by viral vectors for cancer therapy. Molecular Therapy. 2023 Nov 1;31(11):3127-3145.
9. Jennings VA, Ilkow CS. Generation and Quantification of Cytotoxic Lymphocytes Following Oncolytic Virus Infection of Multi-cellular Tumor Spheroids. Methods Mol Biol. 2023;2614:139-149.
10. Whelan JT, Singaravelu R, Wang F, Pelin A, Tamming LA, Pugliese G, Martin NT, Crupi MJF, Petryk J, Austin B, He X, Marius R, Duong J, Jones C, Fekete EEF, Alluqmani N, Chen A, Boulton S, Huh MS, Tang MY, Taha Z, Scut E, Diallo JS, Azad T, Lichty BD, Ilkow CS, Bell JC. CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX. Front Immunol. 2023 Jan 13;13:1050250.
11. Moulin C, Crupi MJF, Ilkow CS, Bell JC, Boulton S. Extracellular Vesicles and Viruses: Two Intertwined Entities. Int J Mol Sci. 2023 Jan 5;24(2):1036.
12. Lalu MM, Presseau J, Foster MK, Hunniford VT, Cobey KD, Brehaut JC, Ilkow CS, Montroy J,Cardenas A, Sharif A, Jeffers MS, Fergusson DA. Identifying barriers and enablers to rigorous conduct and reporting of preclinical laboratory studies. PLoS Biol. 2023 Jan 5;21(1).
13. Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, McComb S, Auer R, Diallo J-S, Ilkow CS, Bell JC. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer. Front Immunol. 2022 Nov 3;13:1029269.
14. Taha Z, Arulanandam R, Maznyi G, Godbout E, Carter-Timofte ME, Kurmasheva N, Reinert LS, Chen A, Crupi MJF, Boulton S, Laroche G, Phan A, Rezaei R, Alluqmani N, Jirovec A, Acal A, Brown EEF, Singaravelu R, Petryk J, Idorn M, Potts KG, Todesco H, John JC, Mahoney DJ, Ilkow CS, Giguère P, Alain T, Côté M, Paludan SR, Olagnier D, Azad T, Diallo J-S. Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen. Molecular Therapy. 2022 May 6:S1525-0016(22)00296-9.
15. Wedge ME, Jennings VA, Pugliese G, Poutou J, Crupi MJF, Jamieson TR, Laight BJ, Boileau M, Khan ST, McKay HE, Pikor L, Pelin A, Rose E, Brown E, Crawford N, Tanese de Souza C, Alkayyal A, Surendran A, Singaravelu R, Roy D, Petryk J, Migneco G, McSweeney B, Cottee ML, Jacobus EJ, Keller B, Chatterjee A, Auer RA, Diallo J-S, Gibbings D, tenOever BR, Melcher A, Bell JC, Ilkow CS. “Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy”. Nature Communications, April 2022.
16. Rangsitratkul C, Lawson C, Bernier-Godon F, Niavarani SR, Boudaud M, Rouleau S, Gladu-Corbin AO, Surendran A, Ekindi-Ndongo N, Koti M, Ilkow CS, Richard PO, Tai LH. Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. Molecular Therapy Oncolytics. 2022 Feb 1;24:507-521.
17. Boulton S, Poutou J, Martin NT, Azad T, Singaravelu R, Crupi MJF, Jamieson T, He X, Marius R, Petryk J, Tanese de Souza C, Austin B, Khan ST, Pelin A, Rezaei R, Surendran A, Tucker S, Brown EMF, Dave J, Diallo J-S, Auer R, Angel JB, Cameron W, Cailhier JF, Lapointe R, Potts K, Mahoney DJ, Bell JC, Ilkow CS. “Single dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection”. Mol Ther. 2022 May 4;30(5):1885-1896.
All Other Publications
Boulton S, Poutou J, Gill R, Alluqmani N, He X, Singaravelu R, Crupi MJF, Petryk J, Austin B, Angka L, Taha Z, Teo I, Singh S, Jamil R, Marius R, Martin N, Jamieson T, Azad T, Diallo JS, Ilkow CS, Bell JC. A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection. Molecular Therapy Methods Clin Dev. 2023 Sep 16;31:101110.
Martin NT, Crupi MJF, Taha Z, Poutou J, Whelan JT, Vallati S, Petryk J, Marius R, Austin B, Azad T, Boulanger M, Burgess T, Sanders I, Victoor C, Dickinson BC, Diallo JS, Ilkow CS, Bell JC. Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy. Pharmaceuticals (Basel). 2023 May 7;16(5):709.
Azad T, Rezaei R, Singaravelu R, Pelin A, Boulton S, Petryk J, Onsu KA, Martin NT, Hoskin V, Ghahremani M, Marotel M, Marius R, He X, Crupi MJF, Hoang HD, Nik-Akhtar A, Ahmadi M, Zamani NK, Golshani A, Alain T, Greer P, Ardolino M, Dickinson BC, Tai LH, Ilkow CS, Bell JC. Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Nature Communications. 2023 May 26;14(1):3035.
Taha Z, Crupi MJF, Alluqmani N, Fareez F, Ng K, Sobh J, Lee E, Chen A, Thomson M, Spinelli MM, Ilkow CS, Bell JC, Arulanandam R, Diallo JS. Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus. Front Immunol. 2023 Apr 19;14:1181014.
Boulton S, Crupi MJF, Singh S, Carter-Timofte ME, Azad T, Organ BC, He X, Gill R, Neault S, Jamieson T, Dave J, Kurmasheva N, Austin B, Petryk J, Singaravelu R, Huang BZ, Franco N, Babu K, Parks RJ, Ilkow CS, Olagnier D, Bell JC. Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development. J Biol Chem. 2023 Jun;299(6):104749.
Surendran A, Jamalkhah M, Poutou J, Birtch R, Lawson C, Dave J, Crupi MJF, Mayer J, Taylor V, Petryk J, de Souza CT, Moodie N, Billingsley JL, Austin B, Cormack N, Blamey N, Rezaei R, McCloskey CW, Fekete EEF, Birdi HK, Neault S, Jamieson TR, Wylie B, Tucker S, Azad T, Vanderhyden B, Tai LH, Bell JC, Ilkow CS. Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment. Front Immunol. 2023 Mar 10;14:1099459.
Rezaei R, Surendran A, Singaravelu R, Jamieson TR, Taklifi P, Poutou J, Azad T, Ilkow CS. “Detection of SARS-CoV-2 RBD antibody using a HiBiT-based bioreporter”. Journal of visualized experiments (JoVE) Published: August 12, 2021.
Marchini A, Ilkow CS, and Melcher A. "Oncolytic Virus Immunotherapy". Cancers 13, no. 15: 3672. July 27, 2021.
PubMed Listings
